Source: International Congress 2014 – Update on lung cancer biology for clinicians



Rating:

Share or cite this content

Citations should be made in the following way:
R.M. Huber (Munich, Germany). Advances in targeted therapy: the clinicians point of view. International Congress 2014 – Update on lung cancer biology for clinicians

Member's Comments

No comment yet.

Related content which might interest you: Advances in treatment of complex lung disease: will targeted therapy with anticalins be clinically applied in the near future? Source: International Congress 2019 – Inhaled medicines and biological therapies in the current era of systemic treatments Year: 2019 The new era of diagnostics: will it ever start? Source: International Congress 2019 – Fighting antimicrobial resistance: from prevention to antimicrobial stewardship Year: 2019 Biologics: current use and future applications for personalised therapy Source: Virtual Congress 2021 – Wheezing illnesses along the life span Year: 2021 Is our approach to basic research right? Pitfalls and successes: what is the way forward? Source: ERS Research Seminar 2016 Year: 2016 How to stop LC-fILD progression: an overview of modern therapeutic strategies Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 At the interface: the translational science supporting the clinical use of anti-cytokine therapy Source: International Congress 2018 – New biologics for asthma: which patients, which agents, which results, at what cost? Year: 2018 Anti-IgE therapy: current knowledge and future perspective Source: International Congress 2019 – The journey towards personalized medicine in asthma: where are we now? Year: 2019 COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020 Year: 2020 Targeting targeted therapies: more choices and the best sequences Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018 What do we need in the clinic and what approach can clinicians take to improve the drug development pipeline? Source: ERS Research Seminar 2016 Year: 2016 Bronchiectasis: new therapies and perspectives Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment Year: 2018 What next? Basic research, new treatments and a patient-centred approach in controlling tuberculosis Source: Eur Respir Monogr 2018; 82: 414-429 Year: 2018 From the bedside: upcoming new clinical strategies Source: International Congress 2016 – Scientific Year in Review 2016 Year: 2016 The new horizons of molecular diagnosis: do we still need conventional microbiology? Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012 Evidence-based medicines for children: important implications for new therapies at all ages Source: Eur Respir J 2006; 28: 1069-1072 Year: 2006 Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities Source: Eur Respir J, 57 (1) 2002349; 10.1183/13993003.02349-2020 Year: 2021